Why the study?
After MI is ruled out, evidence was needed on the prognostic performance of clinical risk scores to inform testing decisions in ED patients.
Do clinical risk scores accurately predict 30-day MACE in adult ED patients with chest pain after MI is ruled out by high-sensitivity troponin?
Systematic Review
Do clinical risk scores accurately predict 30-day MACE in adult ED patients with chest pain after MI is ruled out by high-sensitivity troponin?
While the HEART score (≤3) best identifies low-risk patients, the overall 30-day MACE risk after hs-cTn rule-out is so low that further clinical risk stratification or noninvasive testing may offer little additional value.
Answers are grounded in this paper and cite their sources.
Further stratification or testing may add little value after hs-cTn rule-out; confirms HEART ≤3 as optimal among scores.
BACKGROUND: Chest pain is a common cause for emergency department (ED) presentations. After myocardial infarction (MI) has been ruled out by means of electrocardiography and troponin testing, decisions around anatomic or functional testing may be informed by clinical risk scores. We conducted a systematic review to synthesize evidence of the prognostic performance of chest pain risk scores among ED patients who have had MI ruled out by means of a high-sensitivity troponin assay. METHODS: We queried multiple databases from inception to May 17, 2022. We included studies that quantified risk of 30-day major adverse cardiac events (MACE), at different cutoffs of clinical risk scores, among adult patients who had MI ruled out by means of a high-sensitivity troponin assay. Prognostic performance of each score was synthesized and described, but meta-analysis was not possible. RESULTS: Six studies met inclusion criteria. Short-term MACE risk among patients who had MI ruled out by means of high-sensitivity cardiac troponin assays was very low. The HEART score, with a cutoff of 3 or less, predicted a very low risk of MACE among the greatest proportion of patients. Other scores had lower sensitivity or classified fewer patients as low risk. CONCLUSIONS: The HEART score with a cutoff value of 3 or less accurately identified the greatest number of patients at low risk of 30-day MACE. However, MACE risk among patients who have MI ruled out by means of high-sensitivity troponin testing is sufficiently low that clinical risk stratification or noninvasive testing may be of little additional value in identifying patients with coronary disease.
No takes yet. Share an insight, caveat, or question.
O’Rielly et al. (2023) conducted a systematic review in Chest pain. HEART score vs. Other clinical risk scores was evaluated on 30-day major adverse cardiac events (MACE).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: